Piyasa kapalı· · EUR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Grifols has seen a long share price slide in recent years, which naturally puts the focus on one question for investors who still follow the stock. Is the current price tag properly supported by the earnings the business is generating today. Over the past 5 years the share price has fallen 54%, which makes the current valuation story hinge on whether the market has already absorbed weaker sentiment into the earnings multiple. The group’s ability to turn its plasma based operations into...
European equities traded in the US as American depositary receipts were tracking modestly higher lat
GRFS vs. SDZNY: Which Stock Is the Better Value Option?
European equities traded in the US as American depositary receipts were trending lower late Thursday
GRFS vs. SDZNY: Which Stock Is the Better Value Option?
European equities traded in the US as American depositary receipts were trending slightly higher lat
European equities traded in the US as American depositary receipts were tracking higher late Wednesd
Toronto, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The union that represents Canadian Blood Services (CBS) workers in Ontario is calling for an immediate termination of the blood-plasma collection contract with for-profit Spanish pharmaceutical company Grifols. OPSEU/SEFPO is also calling for an ironclad commitment to ensure that blood and plasma services are never again operated on a for-profit basis. Two people died after donating plasma at Grifols-operated facilities in Winnipeg in October 2025 and J
European equities traded in the US as American depositary receipts were edging higher late Wednesday
TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- Will Trial Lawyers and the Ontario Health Coalition invite members of the media to attend a press conference regarding patient safety issues related to Grifols, one of the world's largest manufacturers of plasma-derived medical products. The media conference will examine issues surrounding public safety and reported adverse events; patients’ legal rights and available supports; regulatory oversight, transparency, and accountability. Speakers will discus
Grifols (NASDAQ:GRFS) is one of the top value stocks to buy under $10. On June 15, Grifols launched FESILTY in the US for treating acute bleeding in pediatric and adult patients with congenital fibrinogen deficiency/CFD, excluding dysfibrinogenemia. This highly purified human-derived fibrinogen concentrate provides a precise, targeted treatment for a rare genetic condition where insufficient […]
The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients. BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new
European equities traded in the US as American depositary receipts were trending higher late Tuesday
European equities traded in the US as American depositary receipts kicked off the week higher late M
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Grifols, S.A. (NASDAQ:GRFS) is among the most undervalued stocks. TheFly reported on May 12 that Deutsche Bank reduced its price target on GRFS from €11 to €10 while reaffirming a Hold rating on the stock. Earlier on May 7, Grifols, […]
European equities traded in the US as American depositary receipts were trending slightly lower late
Analysts have trimmed their fair value price target for Grifols from €15.08 to €14.65, while broader published price targets now cluster in the €10 to €11 range. This reset lines up with a more cautious tone in recent research, where questions around revenue visibility and slower albumin and alpha-1 volumes have led to reduced conviction on upside. As you read on, you will see how this evolving narrative might shape the way you track the stock from here. Analyst Price Targets don't always...
European equities traded in the US as American depositary receipts were trending slightly higher lat
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.